Stanford University cancer screening spinout CAPP Medical has been acquired by Roche.

CAPP Medical, a genomics research spinout from Stanford University, has been acquired by Switzerland-based healthcare research company Roche.

Details of the acquisition have not been disclosed.

The acquisition will allow CAPP Medical to continue working on the development of its technology that screens for cancer and monitors its progress through the detection of tumour DNA circulating in a patient’s blood.

Ashok Krishnamurthi, chief executive of CAPP Medical, said: “This acquisition highlights Roche’s commitment to advancing cancer testing. We strongly believe…